Cupid Limited (CUPID) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Cupid Limited enters its Q1 FY27 results following a record-breaking fiscal year, with investors focused on whether the company can maintain its momentum amidst a volatile raw material environment. The print will be heavily scrutinized for the impact of recent currency tailwinds and the execution status of its ambitious multi-year export programs.

Cupid Limited Q1 Results Date and Time

The board meeting is scheduled for August 07, 2026, to consider the standalone and consolidated unaudited financial results for Q1 FY27.

What to expect from Cupid Limited's Q1 FY27 results

Cupid is expected to report a strong start to FY27, with management having already guided to Q1 revenue exceeding Rs. 150 Cr in a June 30 business update. This performance is supported by the ramp-up of the South Africa 5-year National Condom Program, which provides annual revenue visibility of approximately Rs. 115 Cr. While global natural rubber prices have surged, Cupid's 149-day inventory buffer is likely to insulate gross margins during the quarter, while a weaker rupee provides a material tailwind for its 59.3% export revenue share. Management has already raised its FY27 revenue guidance by 10% to Rs. 660 Cr, reflecting confidence in its dual B2B-B2C growth model and the integration of the Baazar Style Retail ecosystem.

Key Things To Watch

FY27 Guidance Tracking: Monitoring the trajectory against the revised annual revenue target of Rs. 660 Cr.

• Q1 revenue performance against the guided floor of Rs. 150 Cr
• H1/H2 revenue weighting expectations following the upward revision of full-year targets

Capacity and Operational Expansion: Tracking the commissioning of the Palava facility and B2C scaling.

• Palava facility commissioning status with an expected operational timeline in H2 CY2026
• Incremental revenue contribution from the Baazar Style Retail ecosystem across 260+ stores

Operating Metric Trajectory: Assessing the impact of commodity costs and currency movements.

• EBITDA margin sustainability given the inventory buffer against rising natural rubber prices
• Quantification of the USD/INR currency tailwind on reported export revenue and margins

Regulatory and Strategic Milestones: Updates on market access and investment synergies.

• Status of WHO Prequalification for the Malaria IVD kit
• Progress on the US FDA process for the Cupid Version 3 Female Condom
• Expected synergies from the USD 5 Mn follow-on investment in GII Healthcare Investment Limited